Related Experiment Video

Updated: Aug 9, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Population pharmacokinetics of oxycodone in children 6 months to 7 years old

Ahmed El-Tahtawy1, Hannu Kokki, Bruce E Reidenberg

  • 1Metrum Research Group, Tariffville, CT, USA.

Journal of Clinical Pharmacology
|March 24, 2006
PubMed

Insights

Pediatric pain management is improved by understanding oxycodone pharmacokinetics. A population pharmacokinetic model confirms weight-based dosing is effective for children aged 6 months to 7 years.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Pharmacokinetics

Background:

  • Young children frequently receive inadequate pain treatment.
  • Limited understanding of analgesic pharmacokinetics in pediatric populations is a significant barrier.
  • Oxycodone, a common opioid for severe pain, has poorly characterized pharmacokinetics in young children.

Purpose of the Study:

  • To develop a population pharmacokinetic model for oxycodone in young children.
  • To synthesize existing pharmacokinetic data from multiple studies.
  • To inform optimized dosing strategies for pediatric pain management.

Main Methods:

  • Population pharmacokinetic modeling was employed.
  • Data from several studies were combined and analyzed.
  • A two-compartment linear model with route-dependent absorption rates was utilized.

Main Results:

  • A single population model effectively described oxycodone pharmacokinetics across studies.
  • Body weight significantly influenced clearance (CL) and volume of distribution (Vd).
  • The derived allometric scaling model (CL/F=55x(body weight/70)0.87; V/F=86x(body weight/70)1.16) explained interindividual variability.

Conclusions:

  • The developed pharmacokinetic model supports weight-based oxycodone dosing for children aged 6 months to 7 years, irrespective of age.
  • This model is valuable for optimizing pediatric dosing schedules and routes of administration.
  • Improved pharmacokinetic understanding can enhance pain management in young children.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...